Back to Markets
Stocks● Neutral
Cibus pushes US rice to 2029, sees cash to late Q1 2027
Cibus delayed its US gene-edited rice launch to 2029 while confirming a LATAM launch in 2027. Cash runway extends to late Q1 2027. The next decision is execution on 2027 targets.
Continue with
Cibus (CBUS) updated the timeline for its gene-edited rice traits on the Q1 2026 earnings call. The US commercial launch moves to 2029, while the Latin American launch stays on course for 2027. The company also disclosed a cash runway that extends into late Q1 2027 and described its biofragrance business as ramping.
The shift in the US rice timeline removes a near-term revenue catalyst. Gene-edited rice traits had been part of the bull case, with the market pricing in a potential US launch before 2029. Pushing that date out by two years changes the shape of the revenue curve and raises the importance of other value drivers.
US rice launch pushed to 2029
The US launch was originally a nearer-dated catalyst on the Cibus roadmap. Moving it to 2029 means the company does not expect material US rice revenue until the end of the decade. That extends the cash-burn period and keeps Cibus dependent on its non-rice operations to bridge the gap.
Cibus has not disclosed detailed US regulatory or partner timelines publicly. The delay suggests longer development, a tougher regulatory path, or a strategic decision to prioritize resources on the Latin America 2027 launch. The stock reaction will reflect how much the prior valuation embedded an earlier US outcome.
LATAM rice launch still on for 2027
The Latin America rice launch remains on the calendar for 2027. That is now the next binary commercial event for the gene-edited rice platform. Cibus has breeding and regulatory partnerships in the region, and a successful launch would provide a validation point that the technology works at scale in a large rice market.
A 2027 LATAM launch also aligns with the cash runway. If Cibus can generate initial revenue from Latin American rice traits in 2027, it could reduce the need for external funding just as the cash balance approaches its low point. That timeline is tight, however. Any slip in LATAM execution would push the company closer to a capital raise before the rice business contributes.